Evidence map›Paper›PMID 26501506›Full record

Trial reportJAMA neurology2015

Attitudes of Research Participants and the General Public Regarding Disclosure of Alzheimer Disease Research Results.

Jonathan Gooblar, Catherine M Roe, Natalie J Selsor, Matthew J Gabel, John C Morris

Open access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in JAMA neurology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 3 pooled it
5.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 3 syntheses or guidelines pooled it, 75 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Observational
  12. Article
  13. Counseling and disclosure practices in predictive Alzheimer's disease diagnostics: A scoping review.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Article
  14. Amyloid PET disclosure in subjective cognitive decline: Patient experiences over time.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Article
  15. Article
  16. Article
  17. Views and Perceptions of Amyloid Imaging in a Preclinical Alzheimer's Disease Trial.The journal of prevention of Alzheimer's disease · 2024
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Jonathan GooblarDepartment of Psychology, Washington University in St Louis, St Louis, Missouri.
Catherine M RoeKnight Alzheimer Disease Research Center, Washington University in St Louis, St Louis, Missouri3Department of Neurology, Washington University in St Louis, St Louis, Missouri.
Natalie J SelsorKnight Alzheimer Disease Research Center, Washington University in St Louis, St Louis, Missouri.
Matthew J GabelDepartment of Political Science, Washington University in St Louis, St Louis, Missouri.
John C MorrisKnight Alzheimer Disease Research Center, Washington University in St Louis, St Louis, Missouri5Department of Pathology and Immunology, Washington University in St Louis, St Louis, Missouri6Department of Physical Therapy, Washington University in St Louis.
Washington University in St. Louis · US

Funding

Smartphone-Based "Burst" Cognitive AssessmentsP01AG003991 · NIA · WASHINGTON UNIVERSITY · PI JOHN MORRIS · 1985 to 2026
$69.5M
WASHINGTON UNIVERSITY ALZHEIMERS DISEASE RESEARCH CENTERP50AG005681 · NIA · WASHINGTON UNIVERSITY · PI FAGAN, ANNE · 1985 to 2019
$52.1M
The natural history of AB accumulation in preclinical ADP01AG026276 · NIA · WASHINGTON UNIVERSITY · PI MORRIS, JOHN · 2005 to 2025
$49.5M
AGING AND DEVELOPMENTT32AG000030 · NIA · WASHINGTON UNIVERSITY · PI DENISE HEAD, Jeffrey M Zacks · 1985 to 2026
$9.7M
NIA NIH HHS P01 AG003991NIA NIH HHS P01 AG026276NIA NIH HHS P01 AG03991NIA NIH HHS P01 AG26276NIA NIH HHS P50 AG005681NIA NIH HHS P50 AG05681NIA NIH HHS T32 AG000030
6 · The paper itself

Abstract

importanceResults of Alzheimer disease (AD) research assessments typically are not disclosed to participants. Recent research has suggested interest in disclosure, but, to our knowledge, few studies have accounted for awareness of potential benefits and limitations of disclosure.

objectiveTo determine the attitudes of cognitively normal research participants and members of the general public regarding disclosure of AD research results. DESIGN, SETTING, AND

participantsParticipants in a longitudinal aging study (Alzheimer Disease Research Center [ADRC]) were given preintervention and postintervention surveys about disclosure attitudes. In a general public sample (The American Panel Survey), participants responded to a similar survey about disclosure attitudes.

interventionsParticipants in the ADRC sample were randomly assigned to a group (n = 119) that read an education intervention about the usefulness of AD biomarkers or to a placebo group (n = 100) that read as its intervention general information about the ADRC. Participants in the general public sample read a brief vignette describing participation in a longitudinal AD study. MAIN OUTCOME AND MEASURE: Interest in disclosure of AD research results.

resultsCognitively normal ADRC participants (n = 219) were 60.7% (n = 133) female, 83.6% (n = 183) of white race, and reported a mean of 15.91 years of education. Twenty-nine individuals refused participation. The American Panel Survey participants (n = 1418) indicated they did not have AD and were 50.5% (n = 716) female, 76.7% (n = 1087) of white race, and reported a mean of 13.85 years of education. Overall, 77.6% of eligible participants (1583 of 2041) completed the survey in July 2014. Interest in disclosure was high among the ADRC participants (55.1% [119 of 216] were "extremely interested"). Viewing the education intervention predicted lower interest in disclosure (odds ratio, 2.01; 95% CI, 1.15-3.53; P = .02). High subjective risk of AD, a family history of AD, and minimal attendance at research meetings were associated with high interest after the intervention. In the general public, interest was lower overall (12.5% [174 of 1389] were "extremely interested"), but the subset of participants most likely to join an AD research study reported higher interest (43.5% [40 of 92] were extremely interested). CONCLUSIONS AND RELEVANCE: Experience with AD appears to increase interest in disclosure of AD research results. Learning about potential limitations of disclosure somewhat tempered interest. These findings should inform the development of disclosure policies for asymptomatic individuals in AD studies.

Indexed as

AttitudeDisclosureAgedAged, 80 and overAlzheimer DiseaseFemaleHealth SurveysHumansLongitudinal StudiesMaleTeaching

Identifiers

PMID26501506
PMCPMC4694568
OpenAlexW1805220220

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.